Recent advances in understanding hormonal therapy resistant prostate cancer

K. V. Donkena, H. Yuan, C. Y. Young

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may have a slight life prolonging effect on CRPC patients. Interestingly, most of CRPC still express androgen receptor (AR) and depend on the AR for growth. Recently it has been suggested that AR may act as a tumor suppressor in normal prostatic epithelial cells, while in PCa cells AR becomes oncogenic, even under androgen deprivation states. The mechanisms for the latter are still under intensive investigations. A number of studies showed that, in fact, AR signaling is increased under an androgen-depleted environment. The mechanisms suggested in these studies including AR mutations, AR overexpression by gene amplification and other mechanisms that allow activation by low androgen levels or by other endogenous steroids, increased local de novo synthesis of androgens will be discussed. Moreover, developments and tests in clinical trials in CRPC of a number of novel agents interrupting AR signaling mediated PCa growth will also be discussed.

Original languageEnglish (US)
Pages (from-to)402-410
Number of pages9
JournalCurrent Cancer Drug Targets
Volume10
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Castration
Androgens
docetaxel
Therapeutics
Gene Amplification
Growth
Epithelial Cells
Steroids
Clinical Trials
Mutation

Keywords

  • Androgen receptor
  • Castration-resistant prostate cancer
  • Prostate cancer

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Recent advances in understanding hormonal therapy resistant prostate cancer. / Donkena, K. V.; Yuan, H.; Young, C. Y.

In: Current Cancer Drug Targets, Vol. 10, No. 4, 2010, p. 402-410.

Research output: Contribution to journalArticle

Donkena, K. V. ; Yuan, H. ; Young, C. Y. / Recent advances in understanding hormonal therapy resistant prostate cancer. In: Current Cancer Drug Targets. 2010 ; Vol. 10, No. 4. pp. 402-410.
@article{6c36427fbe08435ea4a637e038089400,
title = "Recent advances in understanding hormonal therapy resistant prostate cancer",
abstract = "Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may have a slight life prolonging effect on CRPC patients. Interestingly, most of CRPC still express androgen receptor (AR) and depend on the AR for growth. Recently it has been suggested that AR may act as a tumor suppressor in normal prostatic epithelial cells, while in PCa cells AR becomes oncogenic, even under androgen deprivation states. The mechanisms for the latter are still under intensive investigations. A number of studies showed that, in fact, AR signaling is increased under an androgen-depleted environment. The mechanisms suggested in these studies including AR mutations, AR overexpression by gene amplification and other mechanisms that allow activation by low androgen levels or by other endogenous steroids, increased local de novo synthesis of androgens will be discussed. Moreover, developments and tests in clinical trials in CRPC of a number of novel agents interrupting AR signaling mediated PCa growth will also be discussed.",
keywords = "Androgen receptor, Castration-resistant prostate cancer, Prostate cancer",
author = "Donkena, {K. V.} and H. Yuan and Young, {C. Y.}",
year = "2010",
doi = "10.2174/156800910791208544",
language = "English (US)",
volume = "10",
pages = "402--410",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Recent advances in understanding hormonal therapy resistant prostate cancer

AU - Donkena, K. V.

AU - Yuan, H.

AU - Young, C. Y.

PY - 2010

Y1 - 2010

N2 - Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may have a slight life prolonging effect on CRPC patients. Interestingly, most of CRPC still express androgen receptor (AR) and depend on the AR for growth. Recently it has been suggested that AR may act as a tumor suppressor in normal prostatic epithelial cells, while in PCa cells AR becomes oncogenic, even under androgen deprivation states. The mechanisms for the latter are still under intensive investigations. A number of studies showed that, in fact, AR signaling is increased under an androgen-depleted environment. The mechanisms suggested in these studies including AR mutations, AR overexpression by gene amplification and other mechanisms that allow activation by low androgen levels or by other endogenous steroids, increased local de novo synthesis of androgens will be discussed. Moreover, developments and tests in clinical trials in CRPC of a number of novel agents interrupting AR signaling mediated PCa growth will also be discussed.

AB - Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may have a slight life prolonging effect on CRPC patients. Interestingly, most of CRPC still express androgen receptor (AR) and depend on the AR for growth. Recently it has been suggested that AR may act as a tumor suppressor in normal prostatic epithelial cells, while in PCa cells AR becomes oncogenic, even under androgen deprivation states. The mechanisms for the latter are still under intensive investigations. A number of studies showed that, in fact, AR signaling is increased under an androgen-depleted environment. The mechanisms suggested in these studies including AR mutations, AR overexpression by gene amplification and other mechanisms that allow activation by low androgen levels or by other endogenous steroids, increased local de novo synthesis of androgens will be discussed. Moreover, developments and tests in clinical trials in CRPC of a number of novel agents interrupting AR signaling mediated PCa growth will also be discussed.

KW - Androgen receptor

KW - Castration-resistant prostate cancer

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=77953664477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953664477&partnerID=8YFLogxK

U2 - 10.2174/156800910791208544

DO - 10.2174/156800910791208544

M3 - Article

C2 - 20464780

AN - SCOPUS:77953664477

VL - 10

SP - 402

EP - 410

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 4

ER -